Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study

Not Applicable
Conditions
Prostate Cancer
Interventions
Drug: Docetaxel
Drug: Ketoconazole
First Posted Date
2009-03-27
Last Posted Date
2009-03-27
Lead Sponsor
Kansas City Veteran Affairs Medical Center
Target Recruit Count
20
Registration Number
NCT00870714
Locations
🇺🇸

Kansas City VAMC, Kansas City, Missouri, United States

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

First Posted Date
2009-03-12
Last Posted Date
2011-01-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
30
Registration Number
NCT00860275
Locations
🇺🇸

Ppd Development, Lp, Austin, Texas, United States

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

First Posted Date
2009-03-11
Last Posted Date
2024-05-24
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
55
Registration Number
NCT00859781
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

USC/Norris Comprehensive cancer center, Los Angeles, California, United States

and more 6 locations

Effect of Ketoconazole on Biliary Excretion of AZD0837

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: AZD0837
Drug: ketoconazole
First Posted Date
2008-12-22
Last Posted Date
2010-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT00812344
Locations
🇸🇪

Research Site, Uppsala, Sweden

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

First Posted Date
2008-10-09
Last Posted Date
2009-12-02
Lead Sponsor
VIVUS LLC
Target Recruit Count
44
Registration Number
NCT00770042
Locations
🇺🇸

Research Site, Lincoln, Nebraska, United States

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Phase 1
Completed
Conditions
HCV Infection
Interventions
Drug: ABT-333
Drug: ketoconazole
Drug: placebo
First Posted Date
2008-10-08
Last Posted Date
2010-10-13
Lead Sponsor
Abbott
Target Recruit Count
45
Registration Number
NCT00768690
Locations
🇺🇸

Site Reference ID/Investigator# 12701, Waukegan, Illinois, United States

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
Drug: Rapamycin
Drug: Ketoconazole
First Posted Date
2008-07-02
Last Posted Date
2014-01-17
Lead Sponsor
University of Chicago
Target Recruit Count
57
Registration Number
NCT00708591
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Ketoconazole
Drug: Verapamil
Drug: AZD1305
First Posted Date
2008-07-01
Last Posted Date
2010-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
27
Registration Number
NCT00707551
Locations
🇩🇪

Research Site, Berlin, Germany

STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

Phase 4
Completed
Conditions
Dermatitis, Seborrheic
Interventions
Drug: Ketoconazole
First Posted Date
2008-06-24
Last Posted Date
2017-01-30
Lead Sponsor
Stiefel, a GSK Company
Target Recruit Count
498
Registration Number
NCT00703846

Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel

Phase 2
Completed
Conditions
Solid Tumors
Interventions
Drug: Docetaxel
Drug: Ketoconazole
First Posted Date
2008-06-13
Last Posted Date
2013-12-10
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
10
Registration Number
NCT00697437
Locations
🇸🇬

National University Hospital, Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy